Key result
Intravenous atriopeptin III in rats decreased mean arterial pressure due to a decrease in cardiac output secondary to a fall in stroke volume caused by lowered filling pressure.
Why the study?
Does intravenous atriopeptin III alter systemic haemodynamics in WKY and SHR rats?
Population
Rats of the Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) Okamoto strains
Comparison
Intravenous administration of atriopeptin III vs Baseline (before atriopeptin infusion)
Design
Preclinical
Follow-up
Up to 1 hour
Authors
Loading...
Should not change clinical practice; leaves open whether atriopeptin III hemodynamics translate beyond rat models.
Does intravenous atriopeptin III alter systemic haemodynamics in WKY and SHR rats?
The hypotensive effect of atriopeptin III is driven by a reduction in cardiac output secondary to decreased filling pressure rather than direct vasodilation.
Marks et al. (1987) studied Hypertension. Atriopeptin III vs. Baseline was evaluated on Mean arterial pressure and cardiac output. Intravenous atriopeptin III in rats decreased mean arterial pressure due to a decrease in cardiac output secondary to a fall in stroke volume caused by lowered filling pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: